MedTrace Logo

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

NCT05351554 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-04-17

Study results available
· View outcomes & findings →

Summary

A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.

Conditions

  • Sarcoidosis, Cardiac

Interventions

DRUG

Namilumab

Specified dose on specified days

Sponsors & Collaborators

  • Kinevant Sciences GmbH

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-23
Primary Completion
2022-11-15
Completion
2022-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05351554 on ClinicalTrials.gov